Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Niraparib vs Niraparib in Combination With Bevacizumab in Patients With Carboplatinum-taxane Based Chemotherapy in Advanced Ovarian Cancer (A Multicentre Randomised Phase III Trial)
AGO Study Group
970 participants
Sep 13, 2022
INTERVENTIONAL
Conditions
Summary
This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed by niraparib in patients with newly diagnosed advanced ovarian cancer.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year starting from Cycle 7 Day 1
200 or 300 mg capsules once daily for up to a total of 3 years starting from Cycle 7 Day 1
Locations(65)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05009082